Nutriband Files Provisional Patent to Strengthen AVERSA Abuse-Deterrent Technology Protection

Nutriband Inc. (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, has filed a provisional patent application with the U.S. Patent and Trademark Office to expand protection for its AVERSA abuse-deterrent transdermal technology. The filing covers improved aversive formulations and coating application methods designed to enhance abuse deterrence and increase resistance to tampering.

If converted to a non-provisional patent and granted, the new patent could extend AVERSA's protection by up to 20 years from the filing date. This development is significant because AVERSA technology, already patented in 46 countries, incorporates aversive agents into transdermal patches to prevent misuse of drugs with abuse potential while maintaining accessibility for patients who require them.

The timing of this patent filing comes as the pharmaceutical industry faces increasing pressure to address the opioid crisis and prescription drug abuse epidemic. By strengthening intellectual property protection for abuse-deterrent technologies, Nutriband positions itself at the forefront of developing safer pain management solutions. The company's lead product under development is an abuse-deterrent fentanyl patch incorporating AVERSA technology, which could have substantial implications for patients requiring potent pain medications while reducing diversion risks.

For investors and the healthcare industry, this patent filing represents a strategic move to secure long-term competitive advantage in the growing abuse-deterrent pharmaceutical market. The extended patent protection could provide Nutriband with exclusive rights to these improved formulations through 2044, creating significant barriers to entry for competitors. This development matters because abuse-deterrent technologies represent a critical frontier in balancing legitimate medical needs with public health safety concerns.

The enhanced protection could accelerate adoption of AVERSA technology across multiple drug formulations, potentially impacting global efforts to combat prescription drug abuse. As the company continues development of its transdermal pharmaceutical portfolio, this patent filing strengthens its position in addressing one of healthcare's most pressing challenges. Additional information about the company is available at https://www.nutriband.com, while investors can access the latest news and updates relating to NTRB through the company's newsroom at https://ibn.fm/NTRB.